Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Arvinas Q3 2026 Results: Net Loss of $53.9M, Loss Widens

Arvinas, Inc. reported total assets of $607.5 million as of September 30, 2026, a decrease from $717.9 million at the end of 2025, primarily driven by a reduction in marketable securities and the recognition of deferred revenue. The company maintains a cash runway expected to fund operations into the second half of 2028, focusing on clinical advancements for candidates like ARV-393 and ARV-027.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.541.9
Profit before tax-53.7-34.8
Net income-53.9-35.1
EPS (diluted, $ a share)$-0.82$-0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-98.8%
Source

10-Q filed with the SEC, NASDAQ: ARVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Arvinas, Inc.: key numbers

Share price
$6.77Close, Nov 16
Market cap
$443M
Shares outstanding
65.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Arvinas, Inc.

All →
8:10 AM ET 8-K
Financial Results

Arvinas Financial Results

Arvinas reported third quarter 2026 financial results and provided a corporate update on its protein degrader pipeline, including the initiation of a Phase 1/2 trial for its HPK1 degrader ARV-6723. The company ended the quarter with $1.1 billion in cash and equivalents, which it expects will fund operations into 2028. Key upcoming milestones include Phase 1 data readouts for ARV-393, ARV-027, and ARV-6723 through 2027.

“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders. We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients. The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”

Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.